Strs Ohio Recursion Pharmaceuticals, Inc. Transaction History

Strs Ohio

$25.5 Billion
Q3 2024

A detailed history of Strs Ohio transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Strs Ohio holds 7,900 shares of RXRX stock, worth $50,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,900

Previous 16,100 50.93%

Holding current value

$50,718

Previous $120,000 56.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$5.92 - $8.6 $48,544 - $70,520	-8,200 Reduced 50.93%	7,900 $52,000
Q2 2024 Aug 05, 2024	SELL	$7.35 - $10.05 $30,870 - $42,210	-4,200 Reduced 20.69%	16,100 $120,000
Q1 2024 May 13, 2024	SELL	$9.13 - $15.52 $234,641 - $398,864	-25,700 Reduced 55.87%	20,300 $202,000
Q3 2023 Oct 26, 2023	BUY	$6.59 - $15.86 $155,524 - $374,296	23,600 Added 105.36%	46,000 $351,000
Q2 2023 Jul 31, 2023	BUY	$4.56 - $9.94 $7,751 - $16,898	1,700 Added 8.21%	22,400 $167,000
Q1 2023 Aug 02, 2023	SELL	$6.42 - $9.64 $10,914 - $16,388	-1,700 Reduced 7.59%	20,700 $138,000
Q2 2022 Jul 25, 2022	BUY	$5.04 - $9.26 $30,744 - $56,486	6,100 Added 41.78%	20,700 $168,000
Q1 2022 Apr 21, 2022	SELL	$6.16 - $18.03 $49,280 - $144,240	-8,000 Reduced 35.4%	14,600 $104,000
Q4 2021 Jan 24, 2022	BUY	$16.14 - $21.86 $258,240 - $349,760	16,000 Added 242.42%	22,600 $387,000
Q3 2021 Oct 22, 2021	BUY	$19.03 - $41.33 $32,351 - $70,261	1,700 Added 34.69%	6,600 $151,000
Q2 2021 Jul 26, 2021	BUY	$18.0 - $37.42 $88,200 - $183,358	4,900 New	4,900 $178,000

Others Institutions Holding RXRX

# of Institutions

289

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.16B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account